FDA Plans to Make Rare Disease Drug Review Faster and More Efficient
On October 14, 2026, the U.S. Food and Drug Administration (FDA) released a white paper introducing its Rare Disease Framework Initiative, calling for "fit-for-purpose" evidence to be the norm for every rare disease application. In plain terms, the evidence it asks for would match what can realistically be collected from very small patient populations while holding firm to safety and effectiveness standards.
Why It Matters
Federal law generally defines a rare disease as one affecting fewer than 200,000 people in the United States, yet those numbers add up. About 30 million Americans live with a rare disease, only about 5% of which have an FDA-approved treatment. Rare disease care costs roughly 10 times more per patient than care for common diseases. And without an approved therapy for their rare condition, many patients are treated with therapies approved for other conditions, which is associated with additional health care costs. The FDA recognizes that patients living with rare diseases represent one of the most significant areas of unmet medical need in our country.
What the FDA Is Proposing
The initiative will review the FDA's existing rare disease regulations, guidance and internal processes, from early development through post-approval obligations. The FDA's guiding principles include:
- Greater predictability: Clearer and more consistent communication with drug developers.
- Patient voice: Patient input built in early and at defined milestones.
- Reliance on outside experts: Especially for conditions with very small patient populations. These experts may help inform FDA reviewers as they analyze specific development programs, products, and disease states.
- Risk-based manufacturing review: A risk-based approach to manufacturing review and pre-approval inspections, aimed at getting therapies to patients sooner.
- Modern trial methods: Support for novel trial designs and statistical methods.
Possible outcomes include revised regulations, new or updated guidance, and more consistent practices across the FDA's drug and biologics review centers.
Implications for Drug Manufacturers
Up to now, sponsors have often faced evidence expectations that varied by review division and that presumed there existed patient populations large enough to support traditional trials. If the proposed framework is successful, manufacturers can expect a more collaborative process in which the FDA shapes its requirements to each disease and product.
- Evidence planning: Sponsors should map out early what evidence they can actually obtain, such as natural history data, biomarkers and real-world evidence, and raise their plan with the FDA before Investigational New Drug submission.
- More predictable review: A key goal is consistency across the FDA's Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. This should reduce the risk that one review division asks for something another would not.
- Manufacturing and inspections: A risk-based approach to chemistry, manufacturing and controls review and pre-approval inspections could take pressure off small-batch and individualized therapies, though sponsors should still expect close scrutiny of product quality.
- Incentives in context: The changes come alongside relatively recent legislation. The Consolidated Appropriations Act, 2026, enacted February 3, 2026, limits orphan drug exclusivity to a drug's specific approved use or indication within a rare disease, not the entire disease. This seemingly small change could incentivize drug and biologics manufacturers to create different therapies for various indications within the same rare disease, thereby increasing patient's options for treating their rare disease.
Implications for Hospital Systems
Though discussions of FDA policy usually center on drug manufacturers, the initiative also matters to hospital systems. Providers diagnose and treat rare disease patients, run clinical trials, and absorb high costs when no approved therapy exists.
- Clinical research: The FDA plans to increasingly rely on new trial designs and real-world evidence. Academic medical centers and large systems with research infrastructure may see more sponsor demand for trial sites, patient registries and natural history data.
- Physician experts: The FDA plans to lean more on outside disease experts. Many of these experts are hospital-employed physicians. Systems may want to review their conflict-of-interest and outside-activity policies in light of these proposed changes.
- Earlier access to therapies: Faster approvals could bring new, high-cost therapies to market sooner. Systems should plan for formulary decisions, payer coverage and infusion or administration capacity as new treatment options are approved.
How to Get Involved
The FDA plans to seek input through a public meeting, a Federal Register Request for Information, sector-specific roundtables and internal feedback sessions with FDA staff. Roundtables will include practicing clinicians and hospital systems, who will have a real chance to help shape how evidence is weighed. Providers should identify internal stakeholders and work with patient advocacy partners to coordinate comment. Dates and details will be announced through the FDA's Rare Disease Innovation Hub.
For more information on FDA guidance on biosimilar drug development and the use of comparative efficacy studies, please contact Theodore Thompson or the Stinson LLP contact with whom you regularly work.
